CN103463059A - Application of Lycojaponicumin B in medicine for treating laryngocarcinoma - Google Patents
Application of Lycojaponicumin B in medicine for treating laryngocarcinoma Download PDFInfo
- Publication number
- CN103463059A CN103463059A CN2013104435402A CN201310443540A CN103463059A CN 103463059 A CN103463059 A CN 103463059A CN 2013104435402 A CN2013104435402 A CN 2013104435402A CN 201310443540 A CN201310443540 A CN 201310443540A CN 103463059 A CN103463059 A CN 103463059A
- Authority
- CN
- China
- Prior art keywords
- lycojaponicumin
- medicine
- laryngocarcinoma
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Lycojaponicumin B in preparation of a medicine for treating laryngocarcinoma, which belongs to the technical field of new medicine use. As shown by in vitro MTT antitumor activity evaluation, the Lycojaponicumin B disclosed by the invention also has an excellent inhibitory effect on the growth of human laryngocarcinoma cell strains HEP-2, TU686, M2e and M4e. Therefore, the Lycojaponicumin B can be used for preparing an anti-laryngocarcinoma medicine and has a good development and application prospect. The use of the Lycojaponicumin B related to the invention in the preparation of medicine for treating laryngocarcinoma is disclosed for the first time, the skeleton type belongs to a brand-new skeleton type, and the inhibitory activity of the Lycojaponicumin B on laryngocarcinoma cells is unexpectedly strong.
Description
Technical field
The present invention relates to the new purposes of compound L ycojaponicumin B, relate in particular to the application of Lycojaponicumin B in the anti-laryngeal carcinoma medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be the natural product or derivatives thereof, as paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, searching anticancer compound or lead compound have great importance.
The compound L ycojaponicumin B the present invention relates to is one and within 2012, delivers (Wang, X.J.et al., 2012.Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton fromLycopodium japonicum.Organic Letters14 (10), 2614-2617.) New skeleton compound, this compound has brand-new framework types, belong to open first for the purposes in preparation treatment laryngeal carcinoma medicine the present invention relates to, and because framework types belongs to brand-new framework types, there do not is the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for laryngeal carcinoma simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of compound L ycojaponicumin B in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Lycojaponicumin B in the anti-laryngeal carcinoma medicine of preparation, and the structural formula of LycojaponicuminB is as shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Lycojaponicumin B also has significant inhibitory action to the growth of people's laryngeal cancer cell strain HEP-2, TU686, M2e and M4e, suppresses the IC of this 4 strain Growth of Cells
50value is respectively 1.52 ± 0.17 μ M, 1.25 ± 0.29 μ M, 2.38 ± 0.22 μ M and 3.19 ± 0.36 μ M.Therefore, Lycojaponicumin B can, for the preparation of anti-laryngeal carcinoma medicine, have good development prospect.
The purposes of the Lycojaponicumin B the present invention relates in preparation treatment carcinoma of tongue medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for Human Tongue Carcinoma Lines is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for carcinoma of tongue simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound L ycojaponicumin B involved in the present invention is referring to document (Wang, X.J.et al., 2012.Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum.Organic Letters14 (10), 2614-2617.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound L ycojaponicumin B tablet involved in the present invention:
Get 20 and digest compound Lycojaponicumin B, add conventional adjuvant 180 grams that prepare tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound L ycojaponicumin B capsule involved in the present invention:
Get 20 and digest compound Lycojaponicumin B, add the conventional adjuvant for preparing capsule as starch 180 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Lycojaponicumin B to the strain of people's laryngeal cancer cell
1. method: in the cell of growth logarithmic (log) phase: people's laryngeal cancer cell strain HEP-2, TU686, M2e and M4e(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4the concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24h is adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that the drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Lycojaponicumin B of 0.01 μ M and 0.001 μ M.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10min is placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating the cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank* 100.
2. result: Lycojaponicumin B has significant inhibitory action to the growth of people's laryngeal cancer cell strain HEP-2, TU686, M2e and M4e.This compound suppresses the IC of people's laryngeal cancer cell strain HEP-2, TU686, M2e and M4e growth
50value is respectively: 1.52 ± 0.17 μ M, 1.25 ± 0.29 μ M, 2.38 ± 0.22 μ M and 3.19 ± 0.36 μ M.
By above-described embodiment, shown, Lycojaponicumin B of the present invention has good inhibitory action to the growth of people's laryngeal cancer cell strain HEP-2, TU686, M2e and M4e.Prove thus, Lycojaponicumin B of the present invention has anti-laryngeal carcinoma activity, can be for the preparation of anti-laryngeal carcinoma medicine.
Claims (1)
1.Lycojaponicumin the application of B in treatment laryngeal carcinoma medicine, described compound L ycojaponicumin B structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310443540.2A CN103463059B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin B in preparation treatment laryngeal carcinoma medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310443540.2A CN103463059B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin B in preparation treatment laryngeal carcinoma medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103463059A true CN103463059A (en) | 2013-12-25 |
| CN103463059B CN103463059B (en) | 2015-08-19 |
Family
ID=49788257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310443540.2A Expired - Fee Related CN103463059B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin B in preparation treatment laryngeal carcinoma medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103463059B (en) |
-
2013
- 2013-09-23 CN CN201310443540.2A patent/CN103463059B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| XIAO-JING WANG, ET AL: "Lycojaponicumins A-c,Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum", 《ORGANIC LETTERS》, vol. 14, no. 10, 8 May 2012 (2012-05-08), pages 2614 - 2617, XP055066237, DOI: 10.1021/ol3009478 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103463059B (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861071B (en) | Application of Houttuynoid A in medicine for treating gastric cancer | |
| CN103463046A (en) | Application of Lycojaponicumin A in drugs for treating colorectal cancer | |
| CN103316008A (en) | Application of Aspeverin in preparation of medicine for treating rectal cancer | |
| CN103463059A (en) | Application of Lycojaponicumin B in medicine for treating laryngocarcinoma | |
| CN103479633A (en) | Application of Lycojaponicumin B in preparation of drugs for treating nasopharyngeal carcinoma | |
| CN103463063A (en) | Application of Lycojaponicumin C in preparation of medicines for treating laryngeal cancer | |
| CN103463041A (en) | Application of Lycojaponicumin B in medicine for treating bladder cancer | |
| CN103479630A (en) | Application of Lycojaponicumin A in preparation of drugs for treating breast cancer | |
| CN103463027A (en) | Application of Lycojaponicumin A in medicine for treating laryngocarcinoma | |
| CN103479632A (en) | Application of Lycojaponicumin B in preparation of drugs for treating cervical carcinoma | |
| CN103463049A (en) | Application of Lycojaponicumin B in medicine for treating breast cancer | |
| CN103463054A (en) | Application of Lycojaponicumin A in medicaments for treating bladder cancer | |
| CN103463055A (en) | Application of Lycojaponicumin B in medicine for treating endometrial cancer | |
| CN103463069A (en) | Application of Lycojaponicumin C in preparation of medicines for treating nasopharynx cancer | |
| CN103463045A (en) | Application of Lycojaponicumin A in drugs for treating ileocecal carcinoma | |
| CN103446122A (en) | Application of Lycojaponicumin B in prostate cancer treatment drug | |
| CN103463056A (en) | Application of Lycojaponicumin A in drugs for treating tongue cancer | |
| CN103463050A (en) | Application of Lycojaponicumin A in medicine for treating gastric cancer | |
| CN103463052A (en) | Application of Lycojaponicumin A in drugs for treating cervical cancer | |
| CN103446133A (en) | Application of Lycojaponicumin B in tongue cancer treatment drug | |
| CN103463051A (en) | Application of Lycojaponicumin A in medicaments for treating nasopharyngeal cancer | |
| CN103463078A (en) | Application of Lycojaponicumin C in medicine for treating kidney cancer | |
| CN103463072A (en) | Application of Lycojaponicumin C in medicine for treating bladder cancer | |
| CN103463061A (en) | Application of Lycojaponicumin C in preparation of medicines for treating prostate cancer | |
| CN103463070A (en) | Application of Lycojaponicumin C in preparation of medicines for treating breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171201 Address after: No. 19, Beihai garden shop, No. 99, Yunnan Road, Beihai, the Guangxi Zhuang Autonomous Region Patentee after: Beihai Han Biotechnology Co., Ltd. Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Patentee before: Nanjing Guangkangxie Biomedical Technology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150819 Termination date: 20190923 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |